Report copyright - Tommaso De Pas European Institute of Oncology · Pts without progression received maintenance erlotinib or placebo until progression, unacceptable toxicity or death. FASTACT2 Mok
Please pass captcha verification before submit form
Please pass captcha verification before submit form